Ivermectin B1a 

Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)^[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19^[2].

Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 μg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

875.09

Solid

C₄₈H₇₄O₁₄

71827-03-7

C/C([[email protected]]([[email protected]](/C=C/C=C1CO[[email protected]]([H])([[email protected]@H](C(C)=C[[email protected]]2(C3=O)[H])O)[[email protected]@]\12O)C)O[[email protected]]4(C[[email protected]@H]([[email protected]]([[email protected]@H](O4)C)O[[email protected]@]5(O[[email protected]]([[email protected]@H]([[email protected]](C5)OC)O)C)[H])OC)[H])=C\C[[email protected]@]6(C[[email protected]@]([H])(C[[email protected]@]7(O6)CC[[email protected]@H]([[email protected]]([H])(O7)[[email protected]@H](C)CC)C)O3)[H]

Room temperature in continental US; may vary elsewhere.

• [1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo). 2017 May;70(5):680-684.  [Content Brief]

  [2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23.  [Content Brief]